A method to prevent cross contamination during 2-DE by β-amyloid peptides
Department of Psychiatry and Psychotherapy, University of Duisburg-Essen, LVR-Klinikum, Essen, Germany. Proteomics
(Impact Factor: 3.81).
10/2010; 10(19):3539-43. DOI: 10.1002/pmic.201000227
A method for the efficient decontamination of aluminium oxide ceramic 2-DE focusing trays from β-amyloid peptides (Aβ) is reported. As these contaminations were resistant to the standard cleaning procedures, additional harsh cleaning steps were necessary for their efficient removal. Our observations suggest that specific surface properties affect the degree of adsorption of the Aβ-peptides. "Surface catalysed amyloid aggregation" in the aluminium oxide ceramic trays is proposed as a possible underlying mechanism for the occurrence of proteinase K-resistant forms of Aβ.
Available from: jbc.org
[Show abstract] [Hide abstract]
ABSTRACT: In this study, we report a detailed analysis of the different variants of amyloid-β (Aβ) peptides in the brains and the cerebrospinal
fluid from APP23 transgenic mice, expressing amyloid precursor protein with the Swedish familial Alzheimer disease mutation,
at different ages. Using one- and two-dimensional gel electrophoresis, immunoblotting, and mass spectrometry, we identified
the Aβ peptides Aβ(1–40), -(1–42), -(1–39), -(1–38), -(1–37), -(2–40), and -(3–40) as well as minor amounts of pyroglutamate-modified
Aβ (Aβ(N3pE)) and endogenous murine Aβ in brains from 24-month-old mice. Chemical modifications of the N-terminal amino group
of Aβ were identified that had clearly been introduced during standard experimental procedures. To address this issue, we
additionally applied amyloid extraction in ultrapure water. Clear differences between APP23 mice and Alzheimer disease (AD)
brain samples were observed in terms of the relative abundance of specific variants of Aβ peptides, such as Aβ(N3pE), Aβ(1–42),
and N-terminally truncated Aβ(2/3–42). These differences to human AD amyloid were also noticed in a related mouse line transgenic
for human wild type amyloid precursor protein. Taken together, our findings suggest different underlying molecular mechanisms
driving the amyloid deposition in transgenic mice and AD patients.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.